Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia

Inclusion Criteria

• •Participants must have ulcerative colitis or Crohn's disease with low grade dysplasia or polyploid dysplasia or have a history of dysplasia and increased positive beta-catenin levels confirmed by a consensus of the study pathologists (2 of 2, or 2 of 3)
• •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• •Absolute neutrophil count (ANC) \> 1,500/uL
• •Platelets \> 100,000/uL
• •Total bilirubin within normal institutional limits
• •Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\] =\< 1.5 times upper limit of normal
• •Creatinine within normal institutional limits
• •International normalized ratio (INR) \< 1.5
• •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of baseline pregnancy test, throughout the duration of the study, and for 1 month following cessation of study drug; females must begin adequate contraception immediately following screening pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; if she is pregnant, she will be immediately withdrawn from the study and followed until the birth of the child
• •Ability to understand and the willingness to sign a written informed consent document